Ovidrel (choriogonadotropin alfa) / EMD Serono - LARVOL DELTA

2,000 IU hCG is the optimal dose in a dual hCG/GnRH agonist trigger to achieve comparable pregnancy rates to hCG alone in fresh embryo transfers. (PubMed, J Assist Reprod Genet) - "2,000 IU hCG appears to be the optimal dose in a dual hCG/GnRH agonist trigger, resulting in similar pregnancy outcomes to an hCG trigger and low rates of OHSS among good-responder patients. Ongoing pregnancy rates were significantly lower with hCG doses under 2,000 IU in the dual trigger protocol."

Journal

Impact of Systematic Follicular Flushing on Egg Retrieval and Embryo Quality in IVF-ICSI Cycles: A Controlled Study? (PubMed, J Clin Med) - "A slight increase in slow cleavages was observed (27% vs. 23%, p = 0.04), as well as a lower oocyte maturation rate when ovulation was triggered by Ovitrelle alone...However, the controlled but non-randomised nature of this study requires cautious interpretation of the findings. Larger randomised trials, integrating dynamic assessment technologies, such as time-lapse imaging or oocyte transcriptomic analysis, are needed to refine the clinical indications of this technique and explore its underlying biological mechanisms."

Journal • Gynecology

Embryo division timings and top-quality embryo rates in GnRH-Antagonist ICSI cycles: a comparison of hCG and dual trigger methods. (PubMed, J Assist Reprod Genet) - "Dual triggering in GnRH-antagonist ICSI cycles did not improve most morphokinetic parameters, top-quality embryo rates, or clinical outcomes over hCG alone, suggesting limited benefit in general populations."

Journal

LUTI: Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) (clinicaltrials.gov) - P4 | N=334 | Recruiting | Sponsor: Fundacion Clinic per a la Recerca Biomédica | Active, not recruiting ➔ Recruiting

Enrollment open • Infertility • ENG

LUTI: Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) (clinicaltrials.gov) - P4 | N=334 | Active, not recruiting | Sponsor: Fundacion Clinic per a la Recerca Biomédica

New P4 trial • Infertility • ENG

A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Suzhou Centergene Pharmaceuticals Co.,Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gynecology • Infertility • Sexual Disorders

A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Suzhou Centergene Pharmaceuticals Co.,Ltd.

New P1 trial • Gynecology • Infertility • Sexual Disorders

Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations. (PubMed, Int J Mol Sci) - "Highly purified human menopausal gonadotropin (HP-hMG [Menopur®, Ferring Pharmaceuticals, Saint-Prex, Switzerland]) contains a 1:1 ratio of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)...Brevactid® (urinary hCG; Ferring Pharmaceuticals, Saint-Prex, Switzerland) and Ovidrel® (recombinant hCG; Merck KGaA, Darmstadt, Germany) were used as control samples...The analysis revealed 20-30% of protein impurities and a significant presence of oxidized forms in the HP-hMG samples. These findings are critical for understanding the quality, safety, and clinical profile of HP-hMG."

Journal

DOUBLE TRIGGER IN COS: EMBRYO QUALITY AND SUCCESS RATE (ASPIRE 2024) - "The pregnancy rate obtained in this study was 31.8% vs. 29.5%. Conclusions There are no significant differences were found in embryo quality and pregnancy success rate in patients who received double trigger therapy (Ovidrel and Buserelin) compared to single therapy (Ovidrel)."

Gynecology • Infertility • Sexual Disorders

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: University of Virginia | Trial completion date: May 2024 ➔ May 2026 | Trial primary completion date: Apr 2024 ➔ Apr 2026

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: University of Virginia | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity • Polycystic Ovary Syndrome

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: Mansoura University

New trial • Infertility • Sexual Disorders

A semi-automated hybrid HPLC-MS approach for in-depth characterization of intact non-covalent heterodimer glycoforms of gonadotropin biopharmaceuticals. (PubMed, Anal Chim Acta) - "Human chorionic gonadotropin (hCG) is sold as a biopharmaceutical under the name Pregnyl® (urinary hCG, u-hCG) and Ovitrelle® (recombinant hCG, r-hCG), and recombinant human follicle stimulating hormone (r-hFSH) is marketed as Gonal-f®...The results showed that these biopharmaceuticals differ considerably in their glycosylation patterns and highlight the importance of in-depth characterization of biopharmaceuticals for quality control."

Journal • Infertility • Sexual Disorders

CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) - P1/2 | N=200 | Completed | Sponsor: Lebanese University | Active, not recruiting ➔ Completed | Phase classification: PN/A ➔ P1/2 | Trial completion date: Dec 2021 ➔ May 2023

Phase classification • Trial completion • Trial completion date • Endometriosis • Gynecology • Infectious Disease • Infertility • Polycystic Ovary Syndrome • Sexual Disorders • Uterine Leiomyoma • Women's Health

Progesterone Levels During Ovulation and Luteal Phase (clinicaltrials.gov) - P=N/A | N=6 | Completed | Sponsor: ART Fertility Clinics LLC | Recruiting ➔ Completed

Trial completion • Infertility • Sexual Disorders

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: University of Virginia | Trial completion date: Dec 2023 ➔ May 2024 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

Can Biotin Supplementation be Used to Mask hCG Abuse? (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Sports Medicine Research and Testing Laboratory | Recruiting ➔ Completed | Initiation date: Jul 2022 ➔ Oct 2022 | Trial primary completion date: Aug 2022 ➔ Feb 2023

Trial completion • Trial initiation date • Trial primary completion date

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Ferring Pharmaceuticals | N=500 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Infertility • Sexual Disorders

Analytical investigation of the profile of human chorionic gonadotropin in highly purified human menopausal gonadotrophin preparations (Fertility 2023) - "Objective: Highly-purified human menopausal gonadotropin (HP-hMG [Menopur, Ferring Pharmaceuticals, Switzerland]) contains 1:1 follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity...The reference was a mixture of r-hFSH/follitropin-alfa (GONAL-f), r-hLH/lutropin alfa [Luveris] and r-hCG (Ovidrel) (Merck KGaA, Darmstadt, Germany) constituted based on their reported activity (in IU) in the HP-hMG product label... Advanced molecular analysis of HP-hMG showed that the relative presence of hCG compared to LH may be higher than in the reference, and revealed absence of sulfated glycans, suggesting a mainly placental origin of hCG, with possible impact on receptor affinity/activation and clinical effect."

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=500 | Suspended | Sponsor: Ferring Pharmaceuticals | Recruiting ➔ Suspended

Trial suspension • Infertility • Sexual Disorders

CAN THE DUAL TRIGGER PROTOCOL IMPACT EMBRYO PLOIDIA? (ASRM 2022) - "The groups were Choriomon group with 18 patients (CG), Gonapeptyl group with 452 patients (GG), Lupron group with 67 patients (LG), Ovidrel group with 87 patients (OG), Gonapeptyl plus Choriomon group with 478 patients (GCG). This study demonstrated that the dual trigger protocol was not superior to other trigger protocols and that when compared to the trigger protocol with Gonapeptyl, the dual trigger had a lower rate of embryonic euploidy. IMPACT STATEMENT: The results of this study may assist in the selection of patients who may benefit from the dual trigger protocol. In addition, the study will contribute to the development of new studies to better understand the processes of ovulation induction and its effect on embryonic aneuploidies."

Clinical

IVM-FSHhCG: Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin (clinicaltrials.gov) - P=N/A | N=35 | Recruiting | Sponsor: Universitair Ziekenhuis Brussel | Trial primary completion date: Jun 2022 ➔ Jun 2023

Preclinical • Trial primary completion date

PREDICTIVE VALUES OF PROGESTERONE/ESTRADIOL RATIO ON INTRAUTERINE INSEMINATION OUTCOMES (ASRM 2022) - "Cycles were triggered with recombinant-HCG (Ovitrelle) when the dominant follicle became 18 mm in diameter... The increased P/E2 ratios seven days after insemination were found to be efficient predictive markers of cycle outcome. Further studies, including different stimulation protocols and patients with different infertility diagnoses, are needed in order to confirm the effect of the P/E2 ratio. IMPACT STATEMENT: Based on the obtained results in the presented research, P/E2 ratio measured seven days after intrauterine insemination can be utilized as one of the clinical tests to predict the occurrence of clinical pregnancies."

Infertility • Sexual Disorders

IMPACT OF DUAL TRIGGER WITH GONADOTROPIN RELEASING HORMONE AGONIST & HUMAN CHORIONIC GONADOTROPIN ON IN-VITRO FERTILIZATION CYCLE OUTCOMES OF POSEIDON GROUP 3 & 4 EXPECTED POOR RESPONDER WOMEN (ASRM 2022) - "MATERIALS AND This study was a retrospective analysis of patients with expected poor ovarian response (POR), namely POSEIDON groups 3 and 4 who underwent fresh embryo transfers following antagonist cycles triggered either with dual triggering with GnRH agonist of 0,2 mg triptorelin acetate (Gonapeptyl, Ferring Pharmaceuticals) and 250 mcg recombinant human chorionic gonadotropin (Ovitrelle, Merck Serono) or with hCG-only (250 mcg recombinant human chorionic gonadotropin; Ovitrelle, Merck Serono) trigger between January 2010 and April 2020. Although the advantages of dual-triggering have been well-reported in high- and normo-responders, the currently available literature is controversial about the exact impact in poor responders and not sufficient to make robust evidence based recommendations. Contradictory results of former studies primarily arise from discrepancies in proper categorization of poor responders. Result of this study indicated that dual trigger with GnRH..."

Preclinical • Gynecology

TIFFANY: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation (clinicaltrials.gov) - P2 | N=500 | Recruiting | Sponsor: Ferring Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders